Conformis Inc.
| NASDAQ: CFMS | Healthcare / Medical Devices & Instruments / USA |
| 2.26 | 0 | 0.00 | Vol 6.74K | 1Y Perf 769.23% |
| Sep 1st, 2023 15:57 DELAYED |
| BID | 2.26 | ASK | 2.27 | ||
| Open | 2.26 | Previous Close | 2.26 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 27.67 | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | ★+ — - | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★ — - | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★ — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.00 | Earnings Rating | Sell | |
| Market Cap | 17.80M | Earnings Date | 14th Aug 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.34 | |
| Beta | 1.39 |
Today's Price Range 2.252.27 | 52W Range 1.057.25 | 5 Year PE Ratio Range -1.80-2.20 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | - | ||
| 1 Month | - | ||
| 3 Months | 0.00% | ||
| 6 Months | 96.52% | ||
| 1 Year | 769.23% | ||
| 3 Years | 222.86% | ||
| 5 Years | 343.14% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -25.89 | |||
ROE last 12 Months | -79.24 | |||
ROA (5Y Avg) | -7.87 | |||
ROA last 12 Months | -52.70 | |||
ROC (5Y Avg) | -47.58 | |||
ROC last 12 Months | -52.24 | |||
Return on invested Capital Q | -15.63 | |||
Return on invested Capital Y | -10.80 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 5.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 0.42 | ||||
| 0.57 | ||||
| 27.70 | ||||
| -0.60 | ||||
| -4.56 | ||||
| 0.42 | ||||
| 8.14 | ||||
| -6 192 030.00 | ||||
| Forward PE | -0.48 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.00 | ||||
| 5.10 | ||||
| 0.30 | ||||
| 0.46 | ||||
| -19.10 | ||||
| Leverage Ratio | 1.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 36.60 | ||||
| -99.20 | ||||
| -92.20 | ||||
| -58.40 | ||||
| -99.22 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 44.63M | ||||
| 5.94 | ||||
| 4.12 | ||||
| 2.43 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -1.32 | -1.78 | -34.85 |
| Q01 2023 | -1.56 | -1.32 | 15.38 |
| Q04 2022 | -1.84 | -0.51 | 72.28 |
| Q03 2022 | -1.75 | -2.00 | -14.29 |
| Q02 2022 | -2.00 | -2.25 | -12.50 |
| Q01 2022 | -1.75 | -2.25 | -28.57 |
| Q04 2021 | -2.00 | -2.25 | -12.50 |
| Q03 2021 | -1.75 | -1.75 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -1.40 | 0.00 | - |
| 12/2023 QR | -1.34 | 0.00 | - |
| 12/2023 FY | -5.04 | 3.08 | Positive |
| 12/2024 FY | -4.63 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | -1.32 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 6.74K |
| Shares Outstanding | 7.88K |
| Shares Float | 7.58M |
| Trades Count | 53 |
| Dollar Volume | 15.25K |
| Avg. Volume | 88.16K |
| Avg. Weekly Volume | 55.50K |
| Avg. Monthly Volume | 56.39K |
| Avg. Quarterly Volume | 152.60K |
Conformis Inc. (NASDAQ: CFMS) stock closed at 2.26 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 6.74K shares and market capitalization of 17.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 271 people. Conformis Inc. CEO is Mark A. Augusti.
The one-year performance of Conformis Inc. stock is 769.23%, while year-to-date (YTD) performance is -31.93%. CFMS stock has a five-year performance of 343.14%. Its 52-week range is between 1.05 and 7.25, which gives CFMS stock a 52-week price range ratio of %
Conformis Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.42, a price-to-sale (PS) ratio of 0.57, a price to cashflow ratio of 27.70, a PEG ratio of -, a ROA of -52.70%, a ROC of -52.24% and a ROE of -79.24%. The company’s profit margin is -99.22%, its EBITDA margin is -92.20%, and its revenue ttm is $44.63 Million , which makes it $5.94 revenue per share.
Of the last four earnings reports from Conformis Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.32 for the next earnings report. Conformis Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Conformis Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Conformis Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Conformis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Conformis Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.90, ATR14 : 0.02, CCI20 : 48.84, Chaikin Money Flow : -0.49, MACD : 0.03, Money Flow Index : 25.82, ROC : 0.44, RSI : 74.02, STOCH (14,3) : 66.67, STOCH RSI : 1.00, UO : 17.72, Williams %R : -33.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Conformis Inc. in the last 12-months were:
Conformis Inc.
Conformis Inc is a US-based medical technology company. It uses iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped to fit each patient's anatomy. The company's iFit technology platform comprises three key elements which are iFit design, iFit printing, and iFit just-in-time delivery. It offers various partial and total knee replacement implants which include iTotal CR, iTotal PS, iDuo, and iUni. The company operates in the segment of knee replacement market. Its total revenue generated from the sale of its products to hospitals and other medical facilities. The majority of the company's revenue comes from the United States.
CEO: Mark A. Augusti
Telephone: +1 781 345-9001
Address: 600 Technology Park Drive, Billerica 01821, MA, US
Number of employees: 271
